Prognostic role of nm23 gene expression in patients with ovarian cancer.

Tas F. , Tuzlali S., Aydiner A., Saip P., Salihoglu Y. , Iplikci A., ...Daha Fazla

American journal of clinical oncology, cilt.25, sa.2, ss.164-7, 2002 (SCI Expanded İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Konu: 2
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1097/00000421-200204000-00012
  • Dergi Adı: American journal of clinical oncology
  • Sayfa Sayıları: ss.164-7


The aim of the study was to define the prognostic role of the metastasis suppressor gene, nm23, in 50 patients with primary ovarian cancer. Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded specimens by the primary nm23 monoclonal antibody (Novocastra, NCL-nm23 clone 37.6). Forty-two specimens (84%) showed a positive nm23 staining. The nm23 staining was more intensive in patients with normal serum CA19.9 levels, patients with non-recurrent disease, and alive patients (p < 0.05). Nm23 expression did not correlate with common clinicopathologic parameters such as histology, grade of differentiation, International Federation of Gynecology and Obstetrics stage, and CA-125. Although the difference was not statistically significant (p = 0.11), we found that nm23 may have a favorable prognostic factor in ovarian cancer. To clarify this subject further, prospective studies on a larger population are needed.